Susquehanna International Group, LLP Cyclacel Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

  • $527 Billion
  • Q2 2024

Call Options

4 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 16, 2023
BUY
$0.56 - $1.15 $1,008 - $2,070
1,800 Added 17.65%
12,000 $6,000
Q4 2022

Feb 14, 2023
BUY
$0.54 - $21.75 $5,508 - $221,850
10,200 New
10,200 $6,000
Q4 2021

Feb 14, 2022
SELL
$6.04 - $8.03 $85,164 - $113,222
-14,100 Reduced 58.51%
10,000 $39,000
Q3 2021

Nov 15, 2021
BUY
$8.02 - $11.0 $193,282 - $265,100
24,100 New
24,100 $127,000

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email